Catalyst Capital Advisors’s Transmedics TMDX Stock Holding History

Catalyst Capital Advisors’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$532K	Sell	5,355 -1,220	-19%	-$159K	0.01%	167
2025 Q4	$800K	Sell	6,575 -300	-4%	-$37.6K	0.02%	153
2025 Q3	$771K	Buy	6,875 +3,725	+118%	+$436K	0.02%	153
2025 Q2	$422K	Hold	3,150	–	–	0.01%	191
2025 Q1	$212K	Sell	3,150 -1,650	-34%	-$113K	﹤0.01%	233
2024 Q4	$299K	Hold	4,800	–	–	0.01%	211
2024 Q3	$754K	Sell	4,800 -1,725	-26%	-$266K	0.02%	165
2024 Q2	$983K	Sell	6,525 -975	-13%	-$117K	0.02%	150
2024 Q1	$555K	Buy	+7,500	New	+$618K	0.01%	176
2019 Q3	–	Sell	-435	Closed	-$13K	–	478
2019 Q2	$13K	Buy	+435	New	+$11.9K	﹤0.01%	299

Other funds holding TMDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Capital Advisors's TMDX Position: Q1 2026 in Review

Catalyst Capital Advisors reduced its Transmedics (TMDX) stake by 19% in Q1 2026, selling an estimated $159K and leaving 5,355 shares worth $532K. The position accounts for 0.01% of the portfolio, ranked #167.

Catalyst Capital Advisors first reported a position in TMDX in Q2 2019 and has held it in 10 quarters since. The position peaked at $983K in Q2 2024. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

Catalyst Capital Advisors held 5,355 shares of Transmedics worth $532K as of Q1 2026.
Catalyst Capital Advisors sold 1,220 Transmedics shares in Q1 2026, an estimated $159K.
Transmedics made up 0.01% of Catalyst Capital Advisors's portfolio in Q1 2026, its #167 holding.
Catalyst Capital Advisors first reported a position in Transmedics in Q2 2019 and has held it in 10 quarters since.
Catalyst Capital Advisors's Transmedics position peaked at $983K in Q2 2024.
414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on Catalyst Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.